Physician

Scott Steven Spore, M.D.

According to 2025 Medicare claims, Scott Spore, M.D. (NPI: 1447334867) practices urology in the Lubbock, TX market, with the plurality of this provider's patient population coming from Lubbock, TX. This provider's primary affiliated billing organization is LUBBOCK UROLOGY CLINIC, LLP (NPI: 1629012844; TIN: 751514281) and primary practice location at 79416-3035. Spore is affiliated with the Texoma Clinical Partners ACO, LLC (ACO ID: A4585), Caravan Health ACO 43 LLC (ACO ID: A4974), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Spore's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 758 traditional Medicare patients, billed 16,412 HCPCS/CPT codes, and received $415,330 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,893 prescription claims across 511 beneficiaries totaling $1,157,552 in drug costs, led by Xtandi (Enzalutamide). DME data shows 34 claims. Open Payments data shows 33 records totaling $1,164. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $225,710 to $415,330. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $158,122 to $1,157,552. In contrast, DME billing represents a smaller volume and declined steadily, from $514 to $233.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	713	5,497	$225,710
2016	663	5,517	$211,527
2017	694	5,340	$213,234
2018	712	7,383	$227,081
2019	717	10,679	$240,430
2020	636	11,303	$231,050
2021	673	11,935	$288,299
2022	725	13,250	$288,845
2023	877	15,080	$420,185
2024	758	16,412	$415,330

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	369	1,484	$158,122
2016	347	1,420	$123,526
2017	373	1,352	$120,578
2018	377	1,408	$172,704
2019	425	1,759	$520,105
2020	455	1,800	$815,583
2021	465	1,899	$1,148,879
2022	479	1,876	$1,070,262
2023	483	1,681	$1,085,719
2024	511	1,893	$1,157,552

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	80	$8,458
2016	N/R	21	$6,087
2017	N/R	18	$8,125
2018	N/R	22	$2,004
2019	N/R	N/R	N/R
2020	N/R	11	$1,786
2021	N/R	41	$3,030
2022	N/R	33	$7,390
2023	N/R	40	$9,630
2024	N/R	34	$9,597

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	389	511	$85
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	341	408	$58
36415	Insertion of needle into vein for collection of blood sample	360	523	$9
51798	Ultrasound measurement of bladder capacity after voiding	356	491	$7
81003	Automated urinalysis test	634	946	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	56	1,680	$785,403
Erleada	Apalutamide	12	360	$174,677
Myrbetriq	Mirabegron	104	4,509	$69,997
Xgeva	Denosumab	12	336	$39,261
Gemtesa	Vibegron	38	1,764	$27,424

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4351	Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each	N	N/R	23	$7,145
A4385	Ostomy skin barrier, solid 4 x 4 or equivalent, extended wear, without built-in convexity, each	N	N/R	11	$2,452

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	33	$1,164	Dendreon Pharmaceuticals LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Scott Steven Spore, M.D.?

Tedicare shows public-source Medicare data for Scott Steven Spore, M.D. (NPI 1447334867), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Scott Steven Spore, M.D. have ACO affiliation data?

Scott Steven Spore, M.D. is shown with ACO affiliation data for Texoma Clinical Partners ACO, LLC (MSSP, ACO ID A4585), Caravan Health ACO 43 LLC (MSSP, ACO ID A4974), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Scott Steven Spore, M.D.?

Scott Steven Spore, M.D. is linked to LUBBOCK UROLOGY CLINIC, LLP (billing NPI 1629012844) in the available physician profile data.

Does Scott Steven Spore, M.D. have Open Payments data?

Scott Steven Spore, M.D. has 33 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.